ReviewRSC advances2026
Advances in salivary cortisol monitoring for healthcare applications.
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cortisol is a dynamic endocrine biomarker whose concentration varies with circadian timing, acute stressors, medication, sampling conditions and population characteristics. Saliva provides a non-invasive matrix for repeated measurement of the unbound hormone fraction and is compatible with decentralised point-of-care formats, but salivary cortisol should be interpreted as an adjunctive physiological measure rather than a standalone diagnostic test for psychiatric disorders. This review compares biological sampling matrices and critically evaluates lateral-flow immunoassays, electrochemical, surface-plasmon-resonance and quantum-dot-based cortisol sensors according to recognition chemistry, transduction mechanism, analytical range, sample matrix, validation level and translational readiness. Competitive lateral-flow assays offer rapid, low-cost and discrete measurements, whereas wearable electrochemical and microneedle platforms may support higher-frequency monitoring but face challenges in sample availability, biofouling, calibration drift and long-term stability. Across platforms, very low limits of detection do not by themselves establish suitability for salivary monitoring; physiologically relevant range coverage, authentic-saliva validation, comparison with reference methods and reproducibility are also required. Future progress will depend on standardised collection protocols, selective recognition chemistry, robust digital readout, circadian-aware interpretation and independent clinical validation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.